{"gene":"IL7R","run_date":"2026-06-10T01:55:23","timeline":{"discoveries":[{"year":1998,"finding":"Loss-of-function mutations in IL7R cause T(-)B(+)NK(+) severe combined immunodeficiency (SCID), demonstrating that IL-7Rα signaling is specifically required for T-cell but not NK-cell development in humans.","method":"Genetic analysis of SCID patients with defective IL7R expression; comparison with XSCID and JAK3-SCID phenotypes","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct genetic loss-of-function in human patients with defined immunological phenotype, replicated across multiple patients and consistent with mouse knockout data","pmids":["9843216"],"is_preprint":false},{"year":2004,"finding":"IL-7 and other prosurvival cytokines (IL-2, IL-4, IL-6, IL-15) suppress IL7Rα transcription in T cells, creating a homeostatic mechanism to share limiting IL-7. In CD8+ T cells this involves the transcriptional repressor GFI1, while CD4+ T cells use a different molecular mechanism.","method":"Transcriptional reporter assays, GFI1 functional analysis, cytokine stimulation of primary T cells with measurement of IL7R mRNA","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (transcriptional repression assay, GFI1 identification), replicated across CD4 and CD8 T cell subsets in one rigorous study","pmids":["15308108"],"is_preprint":false},{"year":2009,"finding":"The IL-7Rα ectodomain uses glycosylation to modulate binding to IL-7; glycosylated IL-7Rα binds IL-7 ~300-fold more tightly than unglycosylated IL-7Rα, primarily due to an accelerated on-rate. SCID-causing mutations in IL-7Rα locate outside the IL-7 binding interface, suggesting they cause protein folding defects rather than disrupting direct ligand contact.","method":"Crystal structure of IL-7/IL-7Rα complex (with both glycosylated and unglycosylated receptor), biophysical binding measurements","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with functional binding assays, multiple structural comparisons in one study","pmids":["19141282"],"is_preprint":false},{"year":2010,"finding":"IL-7 triggers rapid clathrin-mediated endocytosis of IL-7Rα, decreases receptor recycling, and accelerates lysosomal and proteasomal degradation, reducing IL-7Rα half-life from ~24 hours to ~3 hours. Clathrin-dependent endocytosis is required for efficient IL-7 signal transduction, and IL-7Rα degradation depends on JAK3 activation.","method":"Live-cell imaging, clathrin inhibitor experiments, JAK3/pan-JAK inhibitor pretreatment, pulse-chase degradation assays in T cells","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (imaging, pharmacological inhibition, half-life measurements) in one study with clear mechanistic readouts","pmids":["20190194"],"is_preprint":false},{"year":2011,"finding":"Somatic gain-of-function mutations in IL7R exon 6 (predominantly introducing an unpaired cysteine in the extracellular juxtamembrane-transmembrane region) found in ~9% of T-ALL patients drive constitutive IL-7Rα homodimerization via intermolecular disulfide bonds and activate JAK1 signaling independently of IL-7, γc, or JAK3, promoting cell transformation and tumor formation.","method":"Biochemical analysis (disulfide bond formation), cytokine-independent growth assays, tumor formation in mice, gene expression profiling","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — reconstitution of constitutive signaling, disulfide bond biochemistry, in vivo tumor formation, replicated by independent study (PMID 21536738)","pmids":["21892159","21536738"],"is_preprint":false},{"year":2011,"finding":"In B-cell precursor ALL, IL7R gain-of-function mutations (serine-to-cysteine at aa185 or transmembrane domain indels) enable formation of a functional receptor with CRLF2 that signals in response to TSLP. A cysteine residue is essential for constitutive receptor activation conferring cytokine-independent growth.","method":"Biochemical and functional assays for cytokine-independent growth, co-expression with CRLF2, cysteine mutagenesis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mutagenesis confirming cysteine requirement, functional cytokine-independent growth assays, receptor complex characterization","pmids":["21536738"],"is_preprint":false},{"year":2011,"finding":"Vps34 (class III PI3K) regulates IL-7Rα intracellular trafficking in T cells. Loss of Vps34 mislocates endosomal markers (Eea1, HRS, Vps36), preventing internalized IL-7Rα from entering the retromer pathway for surface recycling, leading to reduced IL-7Rα surface expression and T lymphocyte death.","method":"Conditional Vps34 knockout mice, subcellular fractionation, endosomal marker localization, IL-7Rα surface expression by flow cytometry","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined trafficking phenotype, multiple endosomal markers analyzed, single lab","pmids":["22021616"],"is_preprint":false},{"year":2008,"finding":"Regulatory T cell development requires IL-7Rα signaling. IL-7Rα-deficient mice have a striking reduction in Treg cells and Foxp3 expression. Either IL-7 or TSLP can provide the required IL-7Rα signal for Treg development in the thymus, as combined loss of IL-7 and TSLP receptor (but not either alone) greatly reduces thymic Treg development.","method":"IL-7Rα−/− mice, IL-7 KO mice, TSLP receptor KO mice, double KO mice; phenotypic analysis by flow cytometry and Foxp3 expression; Treg suppression assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic KO combinations with functional suppression assay readout, establishes epistasis between IL-7 and TSLP ligands for IL-7Rα-dependent Treg development","pmids":["18664628"],"is_preprint":false},{"year":2013,"finding":"Soluble IL-7Rα (sIL-7Rα) has moderate affinity for IL-7 but does not bind TSLP. It competes with cell-associated IL-7R to reduce excessive IL-7 consumption, thereby potentiating IL-7 bioactivity when cytokine is limited. sIL-7Rα also diminishes IL-7 signaling-induced expression of CD95 and SOCS1. In vivo, sIL-7Rα enhances homeostatic T cell expansion and exacerbates experimental autoimmune encephalomyelitis.","method":"Binding affinity measurements, functional IL-7 signaling assays, murine in vivo models of homeostatic expansion and EAE","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct binding measurements plus multiple in vitro and in vivo functional assays in one study","pmids":["23610432"],"is_preprint":false},{"year":2007,"finding":"DNA methylation of the IL7R gene promoter regulates IL-7Rα expression in human T cells. IL-7Rαhigh CD8+ T cells have decreased methylation at the IL7Rα promoter compared with IL-7Rαlow cells. Treatment with the demethylating agent 5-aza-2'-deoxycytidine increased IL-7Rα expression, and unmethylated promoter constructs showed higher luciferase reporter activity.","method":"Bisulfite sequencing of IL7R promoter, 5-aza-2'-deoxycytidine treatment, luciferase reporter assay with methylated vs. unmethylated promoter constructs","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (bisulfite sequencing, pharmacological demethylation, reporter assay), single lab","pmids":["17442928"],"is_preprint":false},{"year":2012,"finding":"IL-7 downregulates IL-7Rα (CD127) surface expression on human CD8+ T cells by two independent mechanisms: (1) early reduction of surface CD127 protein independent of transcriptional suppression and independent of JAK activity; (2) delayed JAK/STAT5-dependent suppression of CD127 transcripts. The magnitude and duration of suppression depend on IL-7 concentration.","method":"Primary human CD8+ T cell stimulation with IL-7, JAK inhibitor treatment, surface protein and mRNA kinetics, dose-response experiments","journal":"Immunology and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection of two pathways with protein and mRNA measurements, single lab","pmids":["23207282"],"is_preprint":false},{"year":2012,"finding":"CPSF1 (cleavage and polyadenylation specificity factor 1) binds a consensus polyadenylation signal (AAUAAA) in intron 6 of IL7R and promotes skipping of exon 6, increasing production of the soluble IL-7Rα isoform. Mutations to this intronic site or CPSF1 knockdown both increase exon 6 inclusion. This establishes competing splicing/polyadenylation as a mechanism regulating the ratio of soluble to membrane-bound IL-7R.","method":"RNA affinity chromatography coupled to mass spectrometry, CPSF1 knockdown, mutagenesis of polyadenylation signal, alternative splicing assays","journal":"RNA","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — affinity chromatography/MS to identify factor, mutagenesis, and KD with consistent results; multiple orthogonal methods","pmids":["23151878"],"is_preprint":false},{"year":2017,"finding":"The RNA helicase DDX39B is a potent activator of IL7R exon 6 inclusion (repressing soluble IL-7Rα production). A genetic variant in the 5' UTR of DDX39B reduces DDX39B translation, increasing soluble IL-7Rα. DDX39B variants show strong genetic and functional epistasis with IL7R exon 6 alleles in determining MS risk.","method":"Genetic epistasis analysis, functional reporter assays for exon 6 splicing, DDX39B overexpression/knockdown, translation reporter assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — functional epistasis with mechanistic splicing assays, translation reporters, and genetic data converging on same conclusion","pmids":["28340352"],"is_preprint":false},{"year":2014,"finding":"IL-7 signaling through IL-7Rα suppresses premature immunoglobulin light-chain rearrangement in developing human B cells. Neutralization of IL-7 in xenogeneic cultures led to increased Ig light-chain rearrangements in CD127+ cells, identifying this as the most definitive function of IL-7 in human B-cell development characterized in this system.","method":"Human/murine xenogeneic B-cell cultures, IL-7 neutralization, IGH locus conformation by 3D FISH, Ig gene rearrangement analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — IL-7 neutralization with direct molecular readout (Ig rearrangement), xenograft model, single lab","pmids":["21680796"],"is_preprint":false},{"year":2014,"finding":"The IL-7Rα Tyr449 cytoplasmic SH2-binding motif is critical for IL-7-mediated pro-B and pre-B cell survival and differentiation in the bone marrow. IL-7Rα(449F/449F) knock-in mice show loss of STAT5 activation and diminished Mcl1 expression in pro-B cells, and defective Igμ rearrangement in pre-B cells. Bcl-2 overexpression does not rescue the pro-B cell defect.","method":"Tyr449Phe knock-in mouse, flow cytometry of B cell stages, STAT5 phosphorylation assay, Bcl-2 transgene rescue experiment, Rag1/Rag2/Irf4 expression analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — knock-in mutagenesis with multiple molecular and cellular readouts, rescue experiment, comparison with full KO","pmids":["25143441"],"is_preprint":false},{"year":2017,"finding":"IL-7Rα polyglutamylation (catalyzed by TTLL4 and TTLL13) and deglutamylation (by CCP2) regulate ILC3 development. IL-7Rα polyglutamylation triggers STAT5 activation and induces transcription factor Sall3 in innate lymphoid progenitors, driving ILC3 differentiation. The IL-7Rα E446A mutation reduces Sall3 expression and the ILC3 population.","method":"CCP2-deficient mice, TTLL4/TTLL13 knockout mice, IL-7Rα E446A knock-in mice, STAT5 phosphorylation, Sall3 expression analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple genetic KO/KI models with consistent molecular mechanism (glutamylation→STAT5→Sall3), site-directed mutagenesis in vivo","pmids":["28794449"],"is_preprint":false},{"year":2020,"finding":"IL-7Rα (γc-shared subunit) sequesters γc by direct binding and pre-association, limiting γc availability for IL-2R assembly. Overexpression of IL-7Rα (including signaling-deficient tailless versions) suppresses IL-2R signaling via extracellular domain interactions, demonstrating that IL-7Rα abundance governs IL-2R signaling capacity and that downregulation of IL-7Rα in Treg cells is mechanistically necessary to maximize IL-2R signaling.","method":"IL-7Rα overexpression (including tailless mutant), IL-2 and IL-7 signaling readouts (STAT5 phosphorylation), co-immunoprecipitation of γc with IL-7Rα","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus functional signaling assays plus tailless mutant to separate extracellular from intracellular effects, single lab","pmids":["32791329"],"is_preprint":false},{"year":2021,"finding":"Overexpression of wild-type IL-7Rα (without activating mutations) is sufficient to drive T-cell leukemogenesis in mice, associated with hyperactivation of PI3K/Akt, Notch, and JAK/STAT signaling pathways, increased Bcl-2, and downregulation of p27Kip1. Established tumors can progress independently of high IL-7Rα levels but remain sensitive to IL-7R-mediated signaling inhibitors.","method":"Tetracycline-inducible Il7r transgenic mice and Rosa26 IL7R knock-in mice; immunophenotyping; pathway inhibitor assays (ruxolitinib, AZD1208, dactolisib, palbociclib, venetoclax)","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent mouse models (inducible transgenic and knock-in) with mechanistic pathway analysis and pharmacological validation","pmids":["33970999"],"is_preprint":false},{"year":2019,"finding":"IL-7R interacts physically with CXCR4 and recruits BCR-ABL1 and JAK kinases in close proximity, forming a molecular platform for BCR-ABL1-induced transformation in Ph+ ALL. BCR-ABL1 kinase inhibitor treatment elevates IL7R expression, enabling leukemia cell survival via IL-7 when combined with inhibitors. Anti-IL-7R antibody treatment prevents leukemia in xenotransplantation models.","method":"Co-immunoprecipitation of IL7R with CXCR4, patient-derived Ph+ ALL xenotransplantation, anti-IL7R antibody treatment, IL7R expression analysis upon kinase inhibitor treatment","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for physical interaction, in vivo xenograft functional validation, single lab","pmids":["32581241"],"is_preprint":false},{"year":2019,"finding":"IL-7R expression is essential for leukemia-initiating cell (LIC) activity in Notch1-induced T-ALL. Il7r-deficient hematopoietic progenitors expressing constitutively active Notch1 fail to generate leukemia in transplantation models. IL-7R expression is an early functional biomarker of T-ALL LIC potential, and impaired IL-7R signaling hampers engraftment of patient-derived T-ALL and B-ALL xenografts.","method":"Genetic loss-of-function (Il7r-deficient mice), Notch1-induced leukemia transplantation model, patient-derived xenograft engraftment assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (Il7r-deficiency in Notch1 model), patient-derived xenografts, multiple leukemia types tested","pmids":["31530562"],"is_preprint":false},{"year":2002,"finding":"IL-7Rα and E47 (E2A) promote lymphoid progenitor development through distinct survival pathways. E2A acts through suppression of caspase-3 activation (not rescued by Bcl-2), whereas IL-7Rα acts through a separate pathway. Mice lacking both IL-7Rα and E47 show a synergistic reduction of T-cell, NK-cell, and multipotent progenitors in the thymus.","method":"Double-knockout mice (IL-7Rα−/− × E47−/−), caspase-3 assays, Bcl-2 overexpression rescue experiment","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with double KO, biochemical pathway differentiation (caspase-3), Bcl-2 rescue experiment","pmids":["11782430"],"is_preprint":false},{"year":2005,"finding":"IL-7Rα is required for proliferative expansion at the pre-BII stage of B-cell development in vivo, independently of the pre-BCR. Both the pre-BCR and IL-7Rα are required for optimal pre-BII cell expansion (double-KO shows greater reduction than either single KO). The pre-BCR does not mediate down-regulation of IL-7Rα, as IL-7Rα expression is normal in pre-BCR-deficient mice.","method":"Pre-BCR/IL-7Rα double-knockout mice, flow cytometric analysis of B-cell stages, IL-7Rα expression in pre-BCR KO mice","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with double KO establishing synergy and ruling out pre-BCR-mediated IL-7Rα regulation","pmids":["15909309"],"is_preprint":false},{"year":2012,"finding":"IL-15 (not IL-7) mediates downregulation of IL-7Rα (CD127) mRNA and protein on memory-phenotype CD8+ T cells in the bone marrow. CD127 mRNA was lower in bone marrow than spleen CD44hi CD8+ T cells. Neither Foxo1 nor IL-7 was responsible for this organ-specific regulation.","method":"Comparison of CD127tg, IL-7 KO, IL-15 KO, IL-15Rα KO and wild-type mice; mRNA quantification; Foxo1 level analysis","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic KO comparisons establishing IL-15 as the responsible factor, single lab","pmids":["22539288"],"is_preprint":false},{"year":2014,"finding":"Notch-RBP-Jκ signaling drives IL-7Rα expression in γδ T cells via a novel IL-7Rα promoter. Conditional RBP-Jκ deletion selectively abolishes IL-7Rα expression on γδ T cells and reduces IL-17+ γδ T cell pool size. Without IL-7Rα-mediated signaling, IL-17+ γδ T cells are barely maintained, and exogenous IL-7 selectively expands this subset in vitro.","method":"Genome-wide Notch target gene analysis, RBP-Jκ conditional KO mice, constitutive Notch signaling in vivo and in vitro, IL-7 supplementation assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genomic identification of novel promoter, genetic KO with specific phenotype, IL-7 functional rescue; single lab","pmids":["25429074"],"is_preprint":false},{"year":2019,"finding":"IL-7Rα is expressed on fetal monocytes during differentiation into tissue-resident macrophages (trMacs). Blockade of IL-7R function during late gestation specifically impairs establishment of fetal-derived trMacs in vivo. Yolk sac erythromyeloid progenitors do not express IL-7R and yolk sac hematopoiesis is unperturbed in IL-7R-deficient mice, demonstrating a distinct fetal myeloid role for IL-7Rα.","method":"Il7r-Cre lineage tracing, IL-7R-deficient mice, IL-7R blockade during gestation, fetal monocyte in vitro differentiation, IL-7Rα surface expression tracking across fetal development","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple complementary approaches (lineage tracing, KO, antibody blockade, in vitro differentiation) converging on same mechanistic conclusion in one study","pmids":["31332039"],"is_preprint":false},{"year":2012,"finding":"IL-7/IL-7Rα signaling withdrawal reduces POT1 protein synthesis, a component of the telomere-protective shelterin complex, leading to telomere erosion and activation of the p53 pathway. In IL-7Rα/p53 double-null mice, loss of apoptosis uncovers augmented thymic lymphomagenesis with chromosomal anomalies.","method":"IL-7Rα null/p53 null double KO mice, POT1 protein expression assays, telomere length analysis, chromosomal analysis of lymphomas","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic double KO with molecular mechanism (POT1 regulation), single lab","pmids":["22281704"],"is_preprint":false},{"year":2015,"finding":"Ikaros directly binds the IL7R promoter and suppresses its expression; loss of Ikaros function in B-ALL is associated with high IL7R expression. Casein kinase inhibition (which increases Ikaros function) suppresses IL7R expression in an Ikaros-dependent manner.","method":"Ikaros ChIP at the IL7R promoter, casein kinase inhibitor treatment, Ikaros knockdown/overexpression with IL7R expression readout","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for direct binding plus pharmacological and genetic perturbation, single lab","pmids":["27322554"],"is_preprint":false},{"year":2022,"finding":"IL-7 signaling through CD127 (IL-7Rα) in monocytes engages STAT5-coordinated transcriptional programs that restrain inflammatory gene expression. CD127-positive monocytes display hypoinflammatory phenotypes within highly inflammatory environments (COVID-19 and rheumatoid arthritis).","method":"Single-cell transcriptomics of human inflammatory monocytes, flow cytometry, functional IL-7 stimulation assays measuring inflammatory gene expression","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — single-cell transcriptomics plus functional IL-7 stimulation experiments, validated in two disease contexts","pmids":["35015026"],"is_preprint":false},{"year":2022,"finding":"IL7Rα, but not Flk2, is intrinsically required for HSC reconstitution of tissue-resident lymphoid cells (B1a, marginal zone B cells, lung ILC2s, and Tregs). IL7Rα-deficient environments also impair TLC reconstitution upon transplantation, revealing a cell-extrinsic (niche) role for IL7Rα in TLC establishment.","method":"Flk2-Cre and Il7r-Cre lineage tracing, Flk2 and IL7Rα single and double KO mice, reciprocal bone marrow transplants","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO and reciprocal transplantation establishing both cell-intrinsic and cell-extrinsic roles, multiple TLC populations analyzed","pmids":["35072209"],"is_preprint":false},{"year":2024,"finding":"Inducible deletion of IL-7Rα specifically on peripheral CD4+ T cells leads to gradual, substantial decrease in CD4+ T cell numbers and prevents EAE development. IL-7Rα-deficient CD4+ T cells show decreased numbers and reduced production of TNF, IFN-γ, IL-17A, GM-CSF, and reduced antigen-specific proliferation.","method":"Il7rafl/fl/CD4CreERT2 inducible conditional KO mice, EAE model, flow cytometry, cytokine production assays, MOG-specific T cell tracking","journal":"Journal of neuroinflammation","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible cell-type-specific KO with clear functional readouts, EAE pathogenesis linkage, antigen-specific T cell analysis","pmids":["39380064"],"is_preprint":false},{"year":2022,"finding":"IL-7 stimulation promotes sCD127 mRNA expression and sCD127 (soluble IL-7Rα) release from CD8+ T cells via a PI3K-dependent pathway, and enhances CD8+ T cell cytotoxicity. PI3K inhibition dampens IL-7-induced elevation of CD8+ T cell cytotoxicity.","method":"IL-7 stimulation of primary human CD8+ T cells, PI3K pathway inhibitors, sCD127 ELISA, mRNA measurement, cytotoxicity co-culture assays","journal":"BMC immunology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological inhibitor used (not genetic), single lab, limited mechanistic depth","pmids":["35850640"],"is_preprint":false},{"year":2016,"finding":"TSLP or IL-7 (both signaling via IL-7Rα) can provide the critical signal for human B-cell production. In vitro human B-cell production is almost completely blocked without IL-7Rα stimulation. In xenograft models, human pro-B cell production depends on IL-7 (neutralizable by anti-IL-7 antibody), and this loss can be restored by physiological levels of human TSLP.","method":"In vitro xenograft models of human B-cell development, IL-7 neutralizing antibody, TSLP supplementation, pro-B cell quantification","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional xenograft model with antibody neutralization and ligand rescue, single lab","pmids":["27325567"],"is_preprint":false}],"current_model":"IL-7Rα (IL7R) is a transmembrane cytokine receptor subunit that, together with γc (IL-2Rγ), forms the functional IL-7 receptor; glycosylation of the IL-7Rα ectodomain dramatically enhances IL-7 binding affinity, and ligand binding triggers JAK1/JAK3-mediated JAK/STAT5, PI3K/Akt, and Notch signaling to drive T-cell (and, in mice, B-cell) development, homeostasis, Treg generation, and ILC development—with receptor internalization via clathrin-coated pits being required for efficient signaling, followed by JAK3-dependent lysosomal/proteasomal degradation; IL7R expression is dynamically regulated at the transcriptional level by DNA methylation, cytokine-induced GFI1-mediated repression, Ikaros, and Notch-RBP-Jκ signaling, and at the post-translational level by IL-7-driven endocytosis and IL-15-dependent downregulation; alternative splicing of exon 6 (regulated by CPSF1 and DDX39B) controls the ratio of membrane-bound to soluble IL-7Rα, with soluble IL-7Rα potentiating IL-7 bioavailability; IL-7Rα sequesters γc by direct extracellular association, limiting IL-2R signaling; gain-of-function mutations introducing unpaired cysteines in the juxtamembrane/transmembrane region drive IL-7Rα homodimerization and constitutive JAK1 signaling independently of ligand, causing T-ALL; and overexpression of wild-type IL-7Rα also promotes T-cell leukemogenesis via PI3K/Akt, JAK/STAT, and Bcl-2 pathways."},"narrative":{"mechanistic_narrative":"IL7R encodes IL-7Rα, the ligand-specific subunit of the IL-7 receptor that, paired with the common γc chain, transduces signals required for lymphoid development and homeostasis; in humans, loss-of-function mutations cause T(-)B(+)NK(+) severe combined immunodeficiency, establishing a non-redundant requirement for IL-7Rα in T-cell but not NK-cell development [PMID:9843216]. Glycosylation of the IL-7Rα ectodomain accelerates the on-rate for IL-7 and raises binding affinity ~300-fold, and SCID mutations map outside the ligand interface, implicating folding defects rather than disrupted contact [PMID:19141282]. Engaged receptor signals through a Tyr449 SH2-binding motif to STAT5, driving Mcl-1 expression and supporting B-lineage survival and immunoglobulin rearrangement [PMID:25143441], and the same receptor controls regulatory T-cell development, where either IL-7 or TSLP can supply the required IL-7Rα signal [PMID:18664628]. Beyond canonical lymphopoiesis, IL-7Rα directs ILC3 differentiation via polyglutamylation-coupled STAT5/Sall3 signaling [PMID:28794449], supports establishment of fetal-derived tissue-resident macrophages [PMID:31332039] and tissue-resident lymphoid cells [PMID:35072209], and restrains inflammatory gene expression in monocytes [PMID:35015026]. Receptor abundance is tightly governed: IL-7 triggers clathrin-mediated endocytosis and JAK3-dependent lysosomal/proteasomal degradation that is itself required for efficient signaling [PMID:20190194], cytokines repress IL7R transcription via GFI1 [PMID:15308108], and DNA methylation [PMID:17442928], Ikaros [PMID:27322554], and Notch–RBP-Jκ [PMID:25429074] further tune expression. Competing splicing/polyadenylation controlled by CPSF1 [PMID:23151878] and the helicase DDX39B [PMID:28340352] sets the ratio of membrane-bound to soluble IL-7Rα, the latter potentiating IL-7 bioavailability and modulating autoimmunity [PMID:23610432]. IL-7Rα also sequesters γc to limit IL-2R signaling, explaining why its downregulation maximizes Treg IL-2 responsiveness [PMID:32791329]. In disease, somatic gain-of-function mutations introducing unpaired cysteines drive ligand-independent IL-7Rα homodimerization and constitutive JAK1 signaling in T-ALL [PMID:21892159, PMID:21536738] or assemble with CRLF2 to signal in B-ALL [PMID:21536738], while overexpression of wild-type IL-7Rα alone is sufficient to promote T-cell leukemogenesis through PI3K/Akt, JAK/STAT, Notch, and Bcl-2 [PMID:33970999], and IL-7Rα is required for leukemia-initiating cell activity [PMID:31530562].","teleology":[{"year":1998,"claim":"Established that IL-7Rα signaling is non-redundantly required for human T-cell development, distinguishing its role from γc and JAK3.","evidence":"Genetic analysis of SCID patients with defective IL7R, compared with XSCID and JAK3-SCID phenotypes","pmids":["9843216"],"confidence":"High","gaps":["Did not resolve which downstream effectors are essential","B-cell and NK lineage requirements left to ortholog studies"]},{"year":2002,"claim":"Defined IL-7Rα as one of two parallel survival inputs for lymphoid progenitors, acting separately from the E2A/caspase-3 pathway.","evidence":"IL-7Rα/E47 double-knockout mice with caspase-3 assays and Bcl-2 rescue","pmids":["11782430"],"confidence":"High","gaps":["Molecular identity of the IL-7Rα survival effector not pinpointed"]},{"year":2004,"claim":"Revealed a homeostatic feedback whereby prosurvival cytokines repress IL7R transcription to share limiting IL-7, identifying GFI1 in CD8 T cells.","evidence":"Transcriptional reporter assays and GFI1 functional analysis in primary T cells","pmids":["15308108"],"confidence":"High","gaps":["CD4 repressor remained unidentified","Did not map GFI1 binding directly on the locus"]},{"year":2009,"claim":"Explained how IL-7Rα achieves high-affinity ligand binding and reframed SCID mutations as folding rather than interface defects.","evidence":"Crystal structure of glycosylated and unglycosylated IL-7/IL-7Rα complex with biophysical binding measurements","pmids":["19141282"],"confidence":"High","gaps":["No structure of the ternary IL-7/IL-7Rα/γc signaling complex","Glycan-specific contributions to signaling not measured"]},{"year":2010,"claim":"Showed receptor internalization is not merely downregulation but a required step for efficient signaling, coupling endocytosis to JAK3-dependent degradation.","evidence":"Live-cell imaging, clathrin and JAK inhibitors, pulse-chase degradation in T cells","pmids":["20190194"],"confidence":"High","gaps":["Adaptor proteins linking IL-7Rα to clathrin not identified","How endocytosis enhances signaling mechanistically unresolved"]},{"year":2011,"claim":"Identified oncogenic gain-of-function mutations that drive ligand-independent IL-7Rα homodimerization and constitutive JAK1 activation in T-ALL, and γc-independent assembly with CRLF2 in B-ALL.","evidence":"Disulfide bond biochemistry, cytokine-independent growth, cysteine mutagenesis, in vivo tumor formation","pmids":["21892159","21536738"],"confidence":"High","gaps":["Did not define why JAK1 rather than JAK3 is engaged","Therapeutic vulnerability not yet mapped in this study"]},{"year":2011,"claim":"Demonstrated that Vps34/class III PI3K routes internalized IL-7Rα through retromer recycling, linking endosomal trafficking to surface receptor levels and T-cell survival.","evidence":"Conditional Vps34 knockout mice, subcellular fractionation, endosomal marker localization, flow cytometry","pmids":["22021616"],"confidence":"Medium","gaps":["Single lab","Direct interaction of retromer with IL-7Rα not shown"]},{"year":2012,"claim":"Established competing splicing/polyadenylation, mediated by CPSF1, as a mechanism setting the soluble-to-membrane IL-7Rα ratio.","evidence":"RNA affinity chromatography/MS, CPSF1 knockdown, polyadenylation-signal mutagenesis, splicing assays","pmids":["23151878"],"confidence":"High","gaps":["Physiological triggers altering CPSF1 activity unclear"]},{"year":2012,"claim":"Dissected IL-7-driven CD127 downregulation into a rapid JAK-independent protein loss and a delayed STAT5-dependent transcriptional suppression.","evidence":"Human CD8 T cell stimulation with JAK inhibitor, protein/mRNA kinetics, dose-response","pmids":["23207282"],"confidence":"Medium","gaps":["Single lab","Mechanism of the early JAK-independent loss not defined"]},{"year":2012,"claim":"Identified IL-15, not IL-7 or Foxo1, as the organ-specific driver of CD127 downregulation on bone marrow memory CD8 T cells.","evidence":"Multiple cytokine and receptor KO mouse comparisons with mRNA quantification","pmids":["22539288"],"confidence":"Medium","gaps":["Single lab","Downstream transcriptional mediator not identified"]},{"year":2012,"claim":"Linked IL-7Rα signaling withdrawal to telomere protection via POT1 and p53, uncovering a tumor-suppressive axis whose loss enables thymic lymphomagenesis.","evidence":"IL-7Rα/p53 double-null mice, POT1 expression, telomere and chromosomal analysis","pmids":["22281704"],"confidence":"Medium","gaps":["Single lab","Mechanism of POT1 translational control not detailed"]},{"year":2013,"claim":"Defined soluble IL-7Rα as a functional modulator that potentiates IL-7 bioactivity and exacerbates autoimmunity by limiting cytokine consumption.","evidence":"Binding affinity measurements plus in vitro signaling and in vivo homeostatic expansion and EAE models","pmids":["23610432"],"confidence":"High","gaps":["In vivo source and concentration thresholds of sIL-7Rα not established"]},{"year":2014,"claim":"Mapped the IL-7Rα Tyr449 STAT5-recruiting motif as essential for B-lineage survival via Mcl-1 and for immunoglobulin rearrangement, distinct from Bcl-2 rescue.","evidence":"Tyr449Phe knock-in mice, STAT5 phosphorylation, Bcl-2 transgene rescue, B-cell staging","pmids":["25143441"],"confidence":"High","gaps":["Other cytoplasmic tyrosines' contributions not resolved"]},{"year":2017,"claim":"Revealed that polyglutamylation/deglutamylation of IL-7Rα tunes STAT5-driven Sall3 induction to control ILC3 development, a non-canonical post-translational regulatory layer.","evidence":"CCP2, TTLL4/TTLL13 KO and IL-7Rα E446A knock-in mice with STAT5 and Sall3 readouts","pmids":["28794449"],"confidence":"High","gaps":["Whether glutamylation regulates other IL-7Rα-dependent lineages unknown"]},{"year":2017,"claim":"Established DDX39B as an activator of IL7R exon 6 inclusion whose translation-reducing variant raises soluble IL-7Rα, with genetic epistasis to IL7R in MS risk.","evidence":"Genetic epistasis, splicing reporters, DDX39B over/knockdown, translation reporters","pmids":["28340352"],"confidence":"High","gaps":["How DDX39B mechanistically promotes exon inclusion not fully resolved"]},{"year":2019,"claim":"Showed IL-7Rα is required for leukemia-initiating cell activity in Notch1-driven T-ALL and for xenograft engraftment across leukemia types.","evidence":"Il7r-deficient Notch1 leukemia transplantation and patient-derived xenografts","pmids":["31530562"],"confidence":"High","gaps":["Effector pathway sustaining LIC self-renewal not isolated"]},{"year":2019,"claim":"Identified a physical IL-7R/CXCR4 platform recruiting BCR-ABL1 and JAKs in Ph+ ALL and a kinase-inhibitor-induced IL7R upregulation enabling survival escape.","evidence":"Co-IP of IL7R with CXCR4, patient-derived xenotransplantation, anti-IL7R antibody treatment","pmids":["32581241"],"confidence":"Medium","gaps":["Single lab","Stoichiometry and directness of the multi-protein platform not fully defined"]},{"year":2019,"claim":"Extended IL-7Rα function beyond lymphocytes by showing it is required to establish fetal-derived tissue-resident macrophages.","evidence":"Il7r-Cre lineage tracing, IL-7R-deficient mice, gestational blockade, in vitro differentiation","pmids":["31332039"],"confidence":"High","gaps":["Signaling output in myeloid context not mechanistically dissected"]},{"year":2020,"claim":"Demonstrated that IL-7Rα abundance limits IL-2R signaling by sequestering γc through extracellular pre-association, rationalizing IL-7Rα downregulation in Tregs.","evidence":"IL-7Rα overexpression including tailless mutant, STAT5 readouts, γc Co-IP","pmids":["32791329"],"confidence":"Medium","gaps":["Single lab","Endogenous physiological relevance beyond overexpression not established"]},{"year":2021,"claim":"Showed wild-type IL-7Rα overexpression alone is sufficient to drive T-cell leukemogenesis via PI3K/Akt, Notch, JAK/STAT and Bcl-2, with pharmacological vulnerabilities.","evidence":"Inducible transgenic and Rosa26 knock-in mice, immunophenotyping, pathway inhibitors","pmids":["33970999"],"confidence":"High","gaps":["Mechanism by which established tumors become IL-7Rα-level-independent unclear"]},{"year":2022,"claim":"Defined an anti-inflammatory IL-7/CD127/STAT5 program in human monocytes, expanding IL-7Rα biology into innate inflammation control.","evidence":"Single-cell transcriptomics and IL-7 stimulation in COVID-19 and rheumatoid arthritis monocytes","pmids":["35015026"],"confidence":"Medium","gaps":["Single study","STAT5 target genes restraining inflammation not enumerated"]},{"year":2022,"claim":"Distinguished cell-intrinsic and niche (extrinsic) roles of IL-7Rα in establishing tissue-resident lymphoid cells beyond conventional lymphopoiesis.","evidence":"Flk2- and Il7r-Cre lineage tracing, single/double KO mice, reciprocal transplants","pmids":["35072209"],"confidence":"High","gaps":["Identity of the IL-7Rα-dependent niche signal not defined"]},{"year":2024,"claim":"Established a continuous peripheral requirement for IL-7Rα on mature CD4 T cells to sustain numbers, effector cytokine output, and autoimmune (EAE) pathogenesis.","evidence":"Inducible CD4-specific IL-7Rα KO mice, EAE model, cytokine and antigen-specific proliferation assays","pmids":["39380064"],"confidence":"High","gaps":["Whether effect reflects survival versus functional reprogramming not fully separated"]},{"year":null,"claim":"How the multiple post-translational regulatory layers (endocytosis, polyglutamylation, γc sequestration) are integrated with transcriptional and splicing control to set context-specific IL-7Rα output remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking trafficking, modification, and isoform balance","Structure of the active signaling complex on the cell surface lacking","Effectors driving non-lymphoid (myeloid, niche) IL-7Rα functions undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,4,14]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[2,8]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[16,8]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,16,2]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[3,6]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[8,11]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,4,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,7,29]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[14,15,24,28]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,5,17,19]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[11,12]}],"complexes":["IL-7 receptor (IL-7Rα/γc)","IL-7Rα/CRLF2 (TSLP receptor)"],"partners":["IL2RG","JAK1","JAK3","CRLF2","CXCR4","STAT5","TTLL4","CCP2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P16871","full_name":"Interleukin-7 receptor subunit alpha","aliases":["CDw127"],"length_aa":459,"mass_kda":51.6,"function":"Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P16871/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IL7R","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IL7R","total_profiled":1310},"omim":[{"mim_id":"620485","title":"TUBULIN TYROSINE LIGASE-LIKE 13; TTLL13","url":"https://www.omim.org/entry/620485"},{"mim_id":"618799","title":"CALCYPHOSINE-LIKE PROTEIN; CAPSL","url":"https://www.omim.org/entry/618799"},{"mim_id":"618738","title":"TUBULIN TYROSINE LIGASE-LIKE 4; TTLL4","url":"https://www.omim.org/entry/618738"},{"mim_id":"617345","title":"ATP/GTP-BINDING PROTEIN-LIKE 2; AGBL2","url":"https://www.omim.org/entry/617345"},{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":171.2}],"url":"https://www.proteinatlas.org/search/IL7R"},"hgnc":{"alias_symbol":["CD127","IL7RA","lnc-IL7R","IL-7Ralpha","IL7Ralpha","sIL-7R","CDw127"],"prev_symbol":[]},"alphafold":{"accession":"P16871","domains":[{"cath_id":"2.60.40.1870","chopping":"41-123","consensus_level":"high","plddt":94.504,"start":41,"end":123},{"cath_id":"2.60.40.10","chopping":"134-228","consensus_level":"high","plddt":95.5922,"start":134,"end":228}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P16871","model_url":"https://alphafold.ebi.ac.uk/files/AF-P16871-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P16871-F1-predicted_aligned_error_v6.png","plddt_mean":67.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IL7R","jax_strain_url":"https://www.jax.org/strain/search?query=IL7R"},"sequence":{"accession":"P16871","fasta_url":"https://rest.uniprot.org/uniprotkb/P16871.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P16871/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P16871"}},"corpus_meta":[{"pmid":"9843216","id":"PMC_9843216","title":"Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9843216","citation_count":602,"is_preprint":false},{"pmid":"15308108","id":"PMC_15308108","title":"Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival.","date":"2004","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15308108","citation_count":386,"is_preprint":false},{"pmid":"21892159","id":"PMC_21892159","title":"Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21892159","citation_count":329,"is_preprint":false},{"pmid":"31745336","id":"PMC_31745336","title":"Flip the coin: IL-7 and IL-7R in health and disease.","date":"2019","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31745336","citation_count":300,"is_preprint":false},{"pmid":"21536738","id":"PMC_21536738","title":"Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21536738","citation_count":281,"is_preprint":false},{"pmid":"22551764","id":"PMC_22551764","title":"IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis.","date":"2012","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22551764","citation_count":206,"is_preprint":false},{"pmid":"24723426","id":"PMC_24723426","title":"The human long noncoding RNA lnc-IL7R regulates the inflammatory response.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24723426","citation_count":165,"is_preprint":false},{"pmid":"26206799","id":"PMC_26206799","title":"Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.","date":"2015","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/26206799","citation_count":135,"is_preprint":false},{"pmid":"15661025","id":"PMC_15661025","title":"Interleukin-7 receptor alpha (IL-7Ralpha) deficiency: cellular and molecular bases. Analysis of clinical, immunological, and molecular features in 16 novel patients.","date":"2005","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15661025","citation_count":128,"is_preprint":false},{"pmid":"23610432","id":"PMC_23610432","title":"Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23610432","citation_count":124,"is_preprint":false},{"pmid":"20690182","id":"PMC_20690182","title":"Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20690182","citation_count":111,"is_preprint":false},{"pmid":"18664628","id":"PMC_18664628","title":"Development of regulatory T cells requires IL-7Ralpha stimulation by IL-7 or TSLP.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18664628","citation_count":105,"is_preprint":false},{"pmid":"20190194","id":"PMC_20190194","title":"IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Ralpha in T cells.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20190194","citation_count":103,"is_preprint":false},{"pmid":"16357322","id":"PMC_16357322","title":"Altered IL-7Ralpha expression with aging and the potential implications of IL-7 therapy on CD8+ T-cell immune responses.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16357322","citation_count":103,"is_preprint":false},{"pmid":"18390743","id":"PMC_18390743","title":"CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18390743","citation_count":101,"is_preprint":false},{"pmid":"36142322","id":"PMC_36142322","title":"The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36142322","citation_count":90,"is_preprint":false},{"pmid":"28340352","id":"PMC_28340352","title":"Human Epistatic Interaction Controls IL7R Splicing and Increases Multiple Sclerosis Risk.","date":"2017","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/28340352","citation_count":85,"is_preprint":false},{"pmid":"16421946","id":"PMC_16421946","title":"IL-7Ralpha expression on CD4+ T lymphocytes decreases with HIV disease progression and inversely correlates with immune activation.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16421946","citation_count":84,"is_preprint":false},{"pmid":"14726805","id":"PMC_14726805","title":"Mutations in genes required for T-cell development: IL7R, CD45, IL2RG, JAK3, RAG1, RAG2, ARTEMIS, and ADA and severe combined immunodeficiency: HuGE review.","date":"2004","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14726805","citation_count":81,"is_preprint":false},{"pmid":"22021616","id":"PMC_22021616","title":"The class III kinase Vps34 promotes T lymphocyte survival through regulating IL-7Rα surface expression.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22021616","citation_count":77,"is_preprint":false},{"pmid":"19141282","id":"PMC_19141282","title":"Structural and biophysical studies of the human IL-7/IL-7Ralpha complex.","date":"2009","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/19141282","citation_count":77,"is_preprint":false},{"pmid":"31332039","id":"PMC_31332039","title":"The lymphoid-associated interleukin 7 receptor (IL7R) regulates tissue-resident macrophage development.","date":"2019","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31332039","citation_count":56,"is_preprint":false},{"pmid":"35595051","id":"PMC_35595051","title":"Significance of IL-7 and IL-7R in RA and autoimmunity.","date":"2022","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35595051","citation_count":55,"is_preprint":false},{"pmid":"35015026","id":"PMC_35015026","title":"CD127 imprints functional heterogeneity to diversify monocyte responses in inflammatory diseases.","date":"2022","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35015026","citation_count":55,"is_preprint":false},{"pmid":"20112030","id":"PMC_20112030","title":"Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility.","date":"2010","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20112030","citation_count":54,"is_preprint":false},{"pmid":"17442928","id":"PMC_17442928","title":"Down-regulation of IL-7Ralpha expression in human T cells via DNA methylation.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17442928","citation_count":53,"is_preprint":false},{"pmid":"12792903","id":"PMC_12792903","title":"Interleukin-7 (IL-7) and IL-7 receptor (IL-7R) signalling complex in human solid tumours.","date":"2003","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/12792903","citation_count":52,"is_preprint":false},{"pmid":"19231135","id":"PMC_19231135","title":"Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients.","date":"2009","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/19231135","citation_count":51,"is_preprint":false},{"pmid":"30850736","id":"PMC_30850736","title":"A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30850736","citation_count":48,"is_preprint":false},{"pmid":"32032632","id":"PMC_32032632","title":"Optimal identification of human conventional and nonconventional (CRTH2-IL7Rα-) ILC2s using additional surface markers.","date":"2020","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32032632","citation_count":47,"is_preprint":false},{"pmid":"33970999","id":"PMC_33970999","title":"Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33970999","citation_count":45,"is_preprint":false},{"pmid":"35243668","id":"PMC_35243668","title":"Single-cell profiling of human CD127+ innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma.","date":"2022","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/35243668","citation_count":44,"is_preprint":false},{"pmid":"11782430","id":"PMC_11782430","title":"IL-7Ralpha and E47: independent pathways required for development of multipotent lymphoid progenitors.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11782430","citation_count":41,"is_preprint":false},{"pmid":"27268088","id":"PMC_27268088","title":"Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/27268088","citation_count":40,"is_preprint":false},{"pmid":"22914435","id":"PMC_22914435","title":"Decreased systemic IL-7 and soluble IL-7Rα in multiple sclerosis patients.","date":"2012","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/22914435","citation_count":40,"is_preprint":false},{"pmid":"31530562","id":"PMC_31530562","title":"IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31530562","citation_count":39,"is_preprint":false},{"pmid":"31594933","id":"PMC_31594933","title":"Context-specific regulation of surface and soluble IL7R expression by an autoimmune risk allele.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31594933","citation_count":37,"is_preprint":false},{"pmid":"30105620","id":"PMC_30105620","title":"Long-Term Health Outcome and Quality of Life Post-HSCT for IL7Rα-, Artemis-, RAG1- and RAG2-Deficient Severe Combined Immunodeficiency: a Single Center Report.","date":"2018","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30105620","citation_count":37,"is_preprint":false},{"pmid":"23151878","id":"PMC_23151878","title":"Cleavage and polyadenylation specificity factor 1 (CPSF1) regulates alternative splicing of interleukin 7 receptor (IL7R) exon 6.","date":"2012","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23151878","citation_count":37,"is_preprint":false},{"pmid":"30883723","id":"PMC_30883723","title":"Expression of IL-7Rα and KLRG1 defines functionally distinct CD8+ T-cell populations in humans.","date":"2019","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30883723","citation_count":36,"is_preprint":false},{"pmid":"22421574","id":"PMC_22421574","title":"The influence of HIV on CD127 expression and its potential implications for IL-7 therapy.","date":"2012","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22421574","citation_count":36,"is_preprint":false},{"pmid":"34226281","id":"PMC_34226281","title":"Expression of KLRG1 and CD127 defines distinct CD8+ subsets that differentially impact patient outcome in follicular lymphoma.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34226281","citation_count":36,"is_preprint":false},{"pmid":"29330114","id":"PMC_29330114","title":"Human CD4+ CD25+ CD127hi cells and the Th1/Th2 phenotype.","date":"2018","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/29330114","citation_count":36,"is_preprint":false},{"pmid":"27325567","id":"PMC_27325567","title":"TSLP or IL-7 provide an IL-7Rα signal that is critical for human B lymphopoiesis.","date":"2016","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27325567","citation_count":35,"is_preprint":false},{"pmid":"32353080","id":"PMC_32353080","title":"Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection.","date":"2020","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/32353080","citation_count":35,"is_preprint":false},{"pmid":"19744146","id":"PMC_19744146","title":"IL7RA polymorphisms and chronic inflammatory arthropathies.","date":"2009","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/19744146","citation_count":35,"is_preprint":false},{"pmid":"27322554","id":"PMC_27322554","title":"Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27322554","citation_count":32,"is_preprint":false},{"pmid":"17595335","id":"PMC_17595335","title":"Prevention of graft-versus-host disease by anti IL-7Ralpha antibody.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17595335","citation_count":32,"is_preprint":false},{"pmid":"35303175","id":"PMC_35303175","title":"Lnc-IL7R alleviates PM2.5-mediated cellular senescence and apoptosis through EZH2 recruitment in chronic obstructive pulmonary disease.","date":"2022","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/35303175","citation_count":31,"is_preprint":false},{"pmid":"31439943","id":"PMC_31439943","title":"New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/31439943","citation_count":31,"is_preprint":false},{"pmid":"28794449","id":"PMC_28794449","title":"IL-7Rα glutamylation and activation of transcription factor Sall3 promote group 3 ILC development.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28794449","citation_count":30,"is_preprint":false},{"pmid":"35264973","id":"PMC_35264973","title":"IL7R Is Correlated With Immune Cell Infiltration in the Tumor Microenvironment of Lung Adenocarcinoma.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35264973","citation_count":29,"is_preprint":false},{"pmid":"23207282","id":"PMC_23207282","title":"IL-7 downregulates IL-7Rα expression in human CD8 T cells by two independent mechanisms.","date":"2012","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23207282","citation_count":27,"is_preprint":false},{"pmid":"21680796","id":"PMC_21680796","title":"IL-7R expression and IL-7 signaling confer a distinct phenotype on developing human B-lineage cells.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21680796","citation_count":26,"is_preprint":false},{"pmid":"25429074","id":"PMC_25429074","title":"A genome-wide analysis identifies a notch-RBP-Jκ-IL-7Rα axis that controls IL-17-producing γδ T cell homeostasis in mice.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25429074","citation_count":26,"is_preprint":false},{"pmid":"15909309","id":"PMC_15909309","title":"Both the pre-BCR and the IL-7Ralpha are essential for expansion at the pre-BII cell stage in vivo.","date":"2005","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15909309","citation_count":26,"is_preprint":false},{"pmid":"22262655","id":"PMC_22262655","title":"The IL-7Rα pathway is quantitatively and functionally altered in CD8 T cells in multiple sclerosis.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22262655","citation_count":25,"is_preprint":false},{"pmid":"20861865","id":"PMC_20861865","title":"IL-7Rα confers susceptibility to experimental autoimmune encephalomyelitis.","date":"2010","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/20861865","citation_count":25,"is_preprint":false},{"pmid":"28138707","id":"PMC_28138707","title":"Lnc‑IL7R promotes the growth of fibroblast‑like synoviocytes through interaction with enhancer of zeste homolog 2 in rheumatoid arthritis.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28138707","citation_count":24,"is_preprint":false},{"pmid":"26297711","id":"PMC_26297711","title":"Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent.","date":"2015","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/26297711","citation_count":23,"is_preprint":false},{"pmid":"39952598","id":"PMC_39952598","title":"The development and potent antitumor efficacy of CD44/CD133 dual-targeting IL7Rα-armored CAR-T cells against glioblastoma.","date":"2025","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/39952598","citation_count":22,"is_preprint":false},{"pmid":"38889332","id":"PMC_38889332","title":"Human CD127 negative ILC2s show immunological memory.","date":"2024","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38889332","citation_count":22,"is_preprint":false},{"pmid":"28446795","id":"PMC_28446795","title":"Variants in the IL7RA gene confer susceptibility to multiple sclerosis in Caucasians: evidence based on 9734 cases and 10436 controls.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28446795","citation_count":22,"is_preprint":false},{"pmid":"22539288","id":"PMC_22539288","title":"IL-15 inhibits IL-7Rα expression by memory-phenotype CD8⁺ T cells in the bone marrow.","date":"2012","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22539288","citation_count":22,"is_preprint":false},{"pmid":"32791329","id":"PMC_32791329","title":"The Cytokine Receptor IL-7Rα Impairs IL-2 Receptor Signaling and Constrains the In Vitro Differentiation of Foxp3+ Treg Cells.","date":"2020","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/32791329","citation_count":22,"is_preprint":false},{"pmid":"31817502","id":"PMC_31817502","title":"Deleterious and Oncogenic Mutations in the IL7RA.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31817502","citation_count":21,"is_preprint":false},{"pmid":"27658954","id":"PMC_27658954","title":"Decreased IL7Rα and TdT expression underlie the skewed immunoglobulin repertoire of human B-cell precursors from fetal origin.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27658954","citation_count":21,"is_preprint":false},{"pmid":"32581241","id":"PMC_32581241","title":"Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32581241","citation_count":21,"is_preprint":false},{"pmid":"25143441","id":"PMC_25143441","title":"The survival and differentiation of pro-B and pre-B cells in the bone marrow is dependent on IL-7Rα Tyr449.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25143441","citation_count":21,"is_preprint":false},{"pmid":"28400540","id":"PMC_28400540","title":"CD56bright NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections.","date":"2017","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/28400540","citation_count":21,"is_preprint":false},{"pmid":"23530149","id":"PMC_23530149","title":"IL7Rα contributes to experimental autoimmune encephalomyelitis through altered T cell responses and nonhematopoietic cell lineages.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23530149","citation_count":20,"is_preprint":false},{"pmid":"22329520","id":"PMC_22329520","title":"Identification of IL7RA risk alleles for rapid progression during HIV-1 infection: a comprehensive study in the GRIV cohort.","date":"2012","source":"Current HIV research","url":"https://pubmed.ncbi.nlm.nih.gov/22329520","citation_count":20,"is_preprint":false},{"pmid":"22281704","id":"PMC_22281704","title":"IL-7Rα deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis.","date":"2012","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/22281704","citation_count":18,"is_preprint":false},{"pmid":"26499378","id":"PMC_26499378","title":"Lack of IL7Rα expression in T cells is a hallmark of T-cell immunodeficiency in Schimke immuno-osseous dysplasia (SIOD).","date":"2015","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/26499378","citation_count":17,"is_preprint":false},{"pmid":"37231145","id":"PMC_37231145","title":"PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells.","date":"2023","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37231145","citation_count":16,"is_preprint":false},{"pmid":"37562671","id":"PMC_37562671","title":"BMI1-induced CD127+KLRG1+ memory T cells enhance the efficacy of liver cancer immunotherapy.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37562671","citation_count":16,"is_preprint":false},{"pmid":"38518105","id":"PMC_38518105","title":"The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.","date":"2024","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/38518105","citation_count":15,"is_preprint":false},{"pmid":"38140726","id":"PMC_38140726","title":"Dexamethasone potentiates chimeric antigen receptor T cell persistence and function by enhancing IL-7Rα expression.","date":"2023","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38140726","citation_count":15,"is_preprint":false},{"pmid":"35581375","id":"PMC_35581375","title":"Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia.","date":"2022","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/35581375","citation_count":15,"is_preprint":false},{"pmid":"31406267","id":"PMC_31406267","title":"Opposing roles of endothelial and leukocyte-expressed IL-7Rα in the regulation of psoriasis-like skin inflammation.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31406267","citation_count":15,"is_preprint":false},{"pmid":"19011158","id":"PMC_19011158","title":"IL-2 receptor gamma chain cytokines differentially regulate human CD8+CD127+ and CD8+CD127- T cell division and susceptibility to apoptosis.","date":"2008","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19011158","citation_count":15,"is_preprint":false},{"pmid":"31379863","id":"PMC_31379863","title":"Reduced Function and Diversity of T Cell Repertoire and Distinct Clinical Course in Patients With IL7RA Mutation.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31379863","citation_count":14,"is_preprint":false},{"pmid":"26402121","id":"PMC_26402121","title":"IL7RA polymorphisms predict the CD4+ recovery in HIV patients on cART.","date":"2015","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26402121","citation_count":14,"is_preprint":false},{"pmid":"32218692","id":"PMC_32218692","title":"Expression of CD4+CD25+CD127Low regulatory T cells and cytokines in peripheral blood of patients with primary liver carcinoma.","date":"2020","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32218692","citation_count":14,"is_preprint":false},{"pmid":"21190413","id":"PMC_21190413","title":"Variation in SNPs of the IL7Ra gene is associated with multiple sclerosis in the Iranian population.","date":"2010","source":"Immunological investigations","url":"https://pubmed.ncbi.nlm.nih.gov/21190413","citation_count":13,"is_preprint":false},{"pmid":"29449560","id":"PMC_29449560","title":"Knockout of zebrafish interleukin 7 receptor (IL7R) by the CRISPR/Cas9 system delays retinal neurodevelopment.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29449560","citation_count":13,"is_preprint":false},{"pmid":"32780913","id":"PMC_32780913","title":"Impaired lnc-IL7R modulatory mechanism of Toll-like receptors is associated with an exacerbator phenotype of chronic obstructive pulmonary disease.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32780913","citation_count":13,"is_preprint":false},{"pmid":"27729062","id":"PMC_27729062","title":"Screening for peptides targeted to IL-7Rα for molecular imaging of rheumatoid arthritis synovium.","date":"2016","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27729062","citation_count":13,"is_preprint":false},{"pmid":"28404633","id":"PMC_28404633","title":"IL-7Rα Expression Regulates Murine Dendritic Cell Sensitivity to Thymic Stromal Lymphopoietin.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28404633","citation_count":12,"is_preprint":false},{"pmid":"15483677","id":"PMC_15483677","title":"IgH DJ rearrangements within T-ALL correlate with cCD79a expression, an immature/TCRgammadelta phenotype and absence of IL7Ralpha/CD127 expression.","date":"2004","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/15483677","citation_count":12,"is_preprint":false},{"pmid":"21543551","id":"PMC_21543551","title":"Relevance of IL7R genotype and mRNA expression in Dutch patients with multiple sclerosis.","date":"2011","source":"Multiple sclerosis (Houndmills, Basingstoke, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21543551","citation_count":12,"is_preprint":false},{"pmid":"35072209","id":"PMC_35072209","title":"IL7Rα, but not Flk2, is required for hematopoietic stem cell reconstitution of tissue-resident lymphoid cells.","date":"2022","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35072209","citation_count":11,"is_preprint":false},{"pmid":"35907923","id":"PMC_35907923","title":"IL-7/IL7R axis dysfunction in adults with severe community-acquired pneumonia (CAP): a cross-sectional study.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35907923","citation_count":11,"is_preprint":false},{"pmid":"21161391","id":"PMC_21161391","title":"Association between the IL7R T244I polymorphism and multiple sclerosis: a meta-analysis.","date":"2010","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21161391","citation_count":11,"is_preprint":false},{"pmid":"35850640","id":"PMC_35850640","title":"Interleukin-7 regulates CD127 expression and promotes CD8+ T cell activity in patients with primary cutaneous melanoma.","date":"2022","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35850640","citation_count":11,"is_preprint":false},{"pmid":"33579907","id":"PMC_33579907","title":"CHBP induces stronger immunosuppressive CD127+ M-MDSC via erythropoietin receptor.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33579907","citation_count":11,"is_preprint":false},{"pmid":"23069254","id":"PMC_23069254","title":"Somatic mutation of IL7R exon 6 in acute leukemias and solid cancers.","date":"2012","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23069254","citation_count":11,"is_preprint":false},{"pmid":"27736699","id":"PMC_27736699","title":"Blockade of IL-7Rα alleviates collagen-induced arthritis via inhibiting Th1 cell differentiation and CD4+ T cell migration.","date":"2016","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27736699","citation_count":11,"is_preprint":false},{"pmid":"39380064","id":"PMC_39380064","title":"IL-7Rα on CD4+ T cells is required for their survival and the pathogenesis of experimental autoimmune encephalomyelitis.","date":"2024","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/39380064","citation_count":10,"is_preprint":false},{"pmid":"31929513","id":"PMC_31929513","title":"IL7RA genetic variants differentially affect IL-7Rα expression and alternative splicing: a role in autoimmune and infectious diseases?","date":"2020","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/31929513","citation_count":10,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50229,"output_tokens":8675,"usd":0.140406,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18718,"output_tokens":6364,"usd":0.126345,"stage2_stop_reason":"end_turn"},"total_usd":0.266751,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"Loss-of-function mutations in IL7R cause T(-)B(+)NK(+) severe combined immunodeficiency (SCID), demonstrating that IL-7Rα signaling is specifically required for T-cell but not NK-cell development in humans.\",\n      \"method\": \"Genetic analysis of SCID patients with defective IL7R expression; comparison with XSCID and JAK3-SCID phenotypes\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct genetic loss-of-function in human patients with defined immunological phenotype, replicated across multiple patients and consistent with mouse knockout data\",\n      \"pmids\": [\"9843216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-7 and other prosurvival cytokines (IL-2, IL-4, IL-6, IL-15) suppress IL7Rα transcription in T cells, creating a homeostatic mechanism to share limiting IL-7. In CD8+ T cells this involves the transcriptional repressor GFI1, while CD4+ T cells use a different molecular mechanism.\",\n      \"method\": \"Transcriptional reporter assays, GFI1 functional analysis, cytokine stimulation of primary T cells with measurement of IL7R mRNA\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (transcriptional repression assay, GFI1 identification), replicated across CD4 and CD8 T cell subsets in one rigorous study\",\n      \"pmids\": [\"15308108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The IL-7Rα ectodomain uses glycosylation to modulate binding to IL-7; glycosylated IL-7Rα binds IL-7 ~300-fold more tightly than unglycosylated IL-7Rα, primarily due to an accelerated on-rate. SCID-causing mutations in IL-7Rα locate outside the IL-7 binding interface, suggesting they cause protein folding defects rather than disrupting direct ligand contact.\",\n      \"method\": \"Crystal structure of IL-7/IL-7Rα complex (with both glycosylated and unglycosylated receptor), biophysical binding measurements\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with functional binding assays, multiple structural comparisons in one study\",\n      \"pmids\": [\"19141282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"IL-7 triggers rapid clathrin-mediated endocytosis of IL-7Rα, decreases receptor recycling, and accelerates lysosomal and proteasomal degradation, reducing IL-7Rα half-life from ~24 hours to ~3 hours. Clathrin-dependent endocytosis is required for efficient IL-7 signal transduction, and IL-7Rα degradation depends on JAK3 activation.\",\n      \"method\": \"Live-cell imaging, clathrin inhibitor experiments, JAK3/pan-JAK inhibitor pretreatment, pulse-chase degradation assays in T cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (imaging, pharmacological inhibition, half-life measurements) in one study with clear mechanistic readouts\",\n      \"pmids\": [\"20190194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Somatic gain-of-function mutations in IL7R exon 6 (predominantly introducing an unpaired cysteine in the extracellular juxtamembrane-transmembrane region) found in ~9% of T-ALL patients drive constitutive IL-7Rα homodimerization via intermolecular disulfide bonds and activate JAK1 signaling independently of IL-7, γc, or JAK3, promoting cell transformation and tumor formation.\",\n      \"method\": \"Biochemical analysis (disulfide bond formation), cytokine-independent growth assays, tumor formation in mice, gene expression profiling\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — reconstitution of constitutive signaling, disulfide bond biochemistry, in vivo tumor formation, replicated by independent study (PMID 21536738)\",\n      \"pmids\": [\"21892159\", \"21536738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In B-cell precursor ALL, IL7R gain-of-function mutations (serine-to-cysteine at aa185 or transmembrane domain indels) enable formation of a functional receptor with CRLF2 that signals in response to TSLP. A cysteine residue is essential for constitutive receptor activation conferring cytokine-independent growth.\",\n      \"method\": \"Biochemical and functional assays for cytokine-independent growth, co-expression with CRLF2, cysteine mutagenesis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mutagenesis confirming cysteine requirement, functional cytokine-independent growth assays, receptor complex characterization\",\n      \"pmids\": [\"21536738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Vps34 (class III PI3K) regulates IL-7Rα intracellular trafficking in T cells. Loss of Vps34 mislocates endosomal markers (Eea1, HRS, Vps36), preventing internalized IL-7Rα from entering the retromer pathway for surface recycling, leading to reduced IL-7Rα surface expression and T lymphocyte death.\",\n      \"method\": \"Conditional Vps34 knockout mice, subcellular fractionation, endosomal marker localization, IL-7Rα surface expression by flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined trafficking phenotype, multiple endosomal markers analyzed, single lab\",\n      \"pmids\": [\"22021616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Regulatory T cell development requires IL-7Rα signaling. IL-7Rα-deficient mice have a striking reduction in Treg cells and Foxp3 expression. Either IL-7 or TSLP can provide the required IL-7Rα signal for Treg development in the thymus, as combined loss of IL-7 and TSLP receptor (but not either alone) greatly reduces thymic Treg development.\",\n      \"method\": \"IL-7Rα−/− mice, IL-7 KO mice, TSLP receptor KO mice, double KO mice; phenotypic analysis by flow cytometry and Foxp3 expression; Treg suppression assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic KO combinations with functional suppression assay readout, establishes epistasis between IL-7 and TSLP ligands for IL-7Rα-dependent Treg development\",\n      \"pmids\": [\"18664628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Soluble IL-7Rα (sIL-7Rα) has moderate affinity for IL-7 but does not bind TSLP. It competes with cell-associated IL-7R to reduce excessive IL-7 consumption, thereby potentiating IL-7 bioactivity when cytokine is limited. sIL-7Rα also diminishes IL-7 signaling-induced expression of CD95 and SOCS1. In vivo, sIL-7Rα enhances homeostatic T cell expansion and exacerbates experimental autoimmune encephalomyelitis.\",\n      \"method\": \"Binding affinity measurements, functional IL-7 signaling assays, murine in vivo models of homeostatic expansion and EAE\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct binding measurements plus multiple in vitro and in vivo functional assays in one study\",\n      \"pmids\": [\"23610432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"DNA methylation of the IL7R gene promoter regulates IL-7Rα expression in human T cells. IL-7Rαhigh CD8+ T cells have decreased methylation at the IL7Rα promoter compared with IL-7Rαlow cells. Treatment with the demethylating agent 5-aza-2'-deoxycytidine increased IL-7Rα expression, and unmethylated promoter constructs showed higher luciferase reporter activity.\",\n      \"method\": \"Bisulfite sequencing of IL7R promoter, 5-aza-2'-deoxycytidine treatment, luciferase reporter assay with methylated vs. unmethylated promoter constructs\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (bisulfite sequencing, pharmacological demethylation, reporter assay), single lab\",\n      \"pmids\": [\"17442928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IL-7 downregulates IL-7Rα (CD127) surface expression on human CD8+ T cells by two independent mechanisms: (1) early reduction of surface CD127 protein independent of transcriptional suppression and independent of JAK activity; (2) delayed JAK/STAT5-dependent suppression of CD127 transcripts. The magnitude and duration of suppression depend on IL-7 concentration.\",\n      \"method\": \"Primary human CD8+ T cell stimulation with IL-7, JAK inhibitor treatment, surface protein and mRNA kinetics, dose-response experiments\",\n      \"journal\": \"Immunology and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection of two pathways with protein and mRNA measurements, single lab\",\n      \"pmids\": [\"23207282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CPSF1 (cleavage and polyadenylation specificity factor 1) binds a consensus polyadenylation signal (AAUAAA) in intron 6 of IL7R and promotes skipping of exon 6, increasing production of the soluble IL-7Rα isoform. Mutations to this intronic site or CPSF1 knockdown both increase exon 6 inclusion. This establishes competing splicing/polyadenylation as a mechanism regulating the ratio of soluble to membrane-bound IL-7R.\",\n      \"method\": \"RNA affinity chromatography coupled to mass spectrometry, CPSF1 knockdown, mutagenesis of polyadenylation signal, alternative splicing assays\",\n      \"journal\": \"RNA\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — affinity chromatography/MS to identify factor, mutagenesis, and KD with consistent results; multiple orthogonal methods\",\n      \"pmids\": [\"23151878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The RNA helicase DDX39B is a potent activator of IL7R exon 6 inclusion (repressing soluble IL-7Rα production). A genetic variant in the 5' UTR of DDX39B reduces DDX39B translation, increasing soluble IL-7Rα. DDX39B variants show strong genetic and functional epistasis with IL7R exon 6 alleles in determining MS risk.\",\n      \"method\": \"Genetic epistasis analysis, functional reporter assays for exon 6 splicing, DDX39B overexpression/knockdown, translation reporter assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — functional epistasis with mechanistic splicing assays, translation reporters, and genetic data converging on same conclusion\",\n      \"pmids\": [\"28340352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IL-7 signaling through IL-7Rα suppresses premature immunoglobulin light-chain rearrangement in developing human B cells. Neutralization of IL-7 in xenogeneic cultures led to increased Ig light-chain rearrangements in CD127+ cells, identifying this as the most definitive function of IL-7 in human B-cell development characterized in this system.\",\n      \"method\": \"Human/murine xenogeneic B-cell cultures, IL-7 neutralization, IGH locus conformation by 3D FISH, Ig gene rearrangement analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — IL-7 neutralization with direct molecular readout (Ig rearrangement), xenograft model, single lab\",\n      \"pmids\": [\"21680796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The IL-7Rα Tyr449 cytoplasmic SH2-binding motif is critical for IL-7-mediated pro-B and pre-B cell survival and differentiation in the bone marrow. IL-7Rα(449F/449F) knock-in mice show loss of STAT5 activation and diminished Mcl1 expression in pro-B cells, and defective Igμ rearrangement in pre-B cells. Bcl-2 overexpression does not rescue the pro-B cell defect.\",\n      \"method\": \"Tyr449Phe knock-in mouse, flow cytometry of B cell stages, STAT5 phosphorylation assay, Bcl-2 transgene rescue experiment, Rag1/Rag2/Irf4 expression analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — knock-in mutagenesis with multiple molecular and cellular readouts, rescue experiment, comparison with full KO\",\n      \"pmids\": [\"25143441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IL-7Rα polyglutamylation (catalyzed by TTLL4 and TTLL13) and deglutamylation (by CCP2) regulate ILC3 development. IL-7Rα polyglutamylation triggers STAT5 activation and induces transcription factor Sall3 in innate lymphoid progenitors, driving ILC3 differentiation. The IL-7Rα E446A mutation reduces Sall3 expression and the ILC3 population.\",\n      \"method\": \"CCP2-deficient mice, TTLL4/TTLL13 knockout mice, IL-7Rα E446A knock-in mice, STAT5 phosphorylation, Sall3 expression analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple genetic KO/KI models with consistent molecular mechanism (glutamylation→STAT5→Sall3), site-directed mutagenesis in vivo\",\n      \"pmids\": [\"28794449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IL-7Rα (γc-shared subunit) sequesters γc by direct binding and pre-association, limiting γc availability for IL-2R assembly. Overexpression of IL-7Rα (including signaling-deficient tailless versions) suppresses IL-2R signaling via extracellular domain interactions, demonstrating that IL-7Rα abundance governs IL-2R signaling capacity and that downregulation of IL-7Rα in Treg cells is mechanistically necessary to maximize IL-2R signaling.\",\n      \"method\": \"IL-7Rα overexpression (including tailless mutant), IL-2 and IL-7 signaling readouts (STAT5 phosphorylation), co-immunoprecipitation of γc with IL-7Rα\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus functional signaling assays plus tailless mutant to separate extracellular from intracellular effects, single lab\",\n      \"pmids\": [\"32791329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Overexpression of wild-type IL-7Rα (without activating mutations) is sufficient to drive T-cell leukemogenesis in mice, associated with hyperactivation of PI3K/Akt, Notch, and JAK/STAT signaling pathways, increased Bcl-2, and downregulation of p27Kip1. Established tumors can progress independently of high IL-7Rα levels but remain sensitive to IL-7R-mediated signaling inhibitors.\",\n      \"method\": \"Tetracycline-inducible Il7r transgenic mice and Rosa26 IL7R knock-in mice; immunophenotyping; pathway inhibitor assays (ruxolitinib, AZD1208, dactolisib, palbociclib, venetoclax)\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent mouse models (inducible transgenic and knock-in) with mechanistic pathway analysis and pharmacological validation\",\n      \"pmids\": [\"33970999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IL-7R interacts physically with CXCR4 and recruits BCR-ABL1 and JAK kinases in close proximity, forming a molecular platform for BCR-ABL1-induced transformation in Ph+ ALL. BCR-ABL1 kinase inhibitor treatment elevates IL7R expression, enabling leukemia cell survival via IL-7 when combined with inhibitors. Anti-IL-7R antibody treatment prevents leukemia in xenotransplantation models.\",\n      \"method\": \"Co-immunoprecipitation of IL7R with CXCR4, patient-derived Ph+ ALL xenotransplantation, anti-IL7R antibody treatment, IL7R expression analysis upon kinase inhibitor treatment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for physical interaction, in vivo xenograft functional validation, single lab\",\n      \"pmids\": [\"32581241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IL-7R expression is essential for leukemia-initiating cell (LIC) activity in Notch1-induced T-ALL. Il7r-deficient hematopoietic progenitors expressing constitutively active Notch1 fail to generate leukemia in transplantation models. IL-7R expression is an early functional biomarker of T-ALL LIC potential, and impaired IL-7R signaling hampers engraftment of patient-derived T-ALL and B-ALL xenografts.\",\n      \"method\": \"Genetic loss-of-function (Il7r-deficient mice), Notch1-induced leukemia transplantation model, patient-derived xenograft engraftment assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (Il7r-deficiency in Notch1 model), patient-derived xenografts, multiple leukemia types tested\",\n      \"pmids\": [\"31530562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IL-7Rα and E47 (E2A) promote lymphoid progenitor development through distinct survival pathways. E2A acts through suppression of caspase-3 activation (not rescued by Bcl-2), whereas IL-7Rα acts through a separate pathway. Mice lacking both IL-7Rα and E47 show a synergistic reduction of T-cell, NK-cell, and multipotent progenitors in the thymus.\",\n      \"method\": \"Double-knockout mice (IL-7Rα−/− × E47−/−), caspase-3 assays, Bcl-2 overexpression rescue experiment\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with double KO, biochemical pathway differentiation (caspase-3), Bcl-2 rescue experiment\",\n      \"pmids\": [\"11782430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IL-7Rα is required for proliferative expansion at the pre-BII stage of B-cell development in vivo, independently of the pre-BCR. Both the pre-BCR and IL-7Rα are required for optimal pre-BII cell expansion (double-KO shows greater reduction than either single KO). The pre-BCR does not mediate down-regulation of IL-7Rα, as IL-7Rα expression is normal in pre-BCR-deficient mice.\",\n      \"method\": \"Pre-BCR/IL-7Rα double-knockout mice, flow cytometric analysis of B-cell stages, IL-7Rα expression in pre-BCR KO mice\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with double KO establishing synergy and ruling out pre-BCR-mediated IL-7Rα regulation\",\n      \"pmids\": [\"15909309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IL-15 (not IL-7) mediates downregulation of IL-7Rα (CD127) mRNA and protein on memory-phenotype CD8+ T cells in the bone marrow. CD127 mRNA was lower in bone marrow than spleen CD44hi CD8+ T cells. Neither Foxo1 nor IL-7 was responsible for this organ-specific regulation.\",\n      \"method\": \"Comparison of CD127tg, IL-7 KO, IL-15 KO, IL-15Rα KO and wild-type mice; mRNA quantification; Foxo1 level analysis\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic KO comparisons establishing IL-15 as the responsible factor, single lab\",\n      \"pmids\": [\"22539288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Notch-RBP-Jκ signaling drives IL-7Rα expression in γδ T cells via a novel IL-7Rα promoter. Conditional RBP-Jκ deletion selectively abolishes IL-7Rα expression on γδ T cells and reduces IL-17+ γδ T cell pool size. Without IL-7Rα-mediated signaling, IL-17+ γδ T cells are barely maintained, and exogenous IL-7 selectively expands this subset in vitro.\",\n      \"method\": \"Genome-wide Notch target gene analysis, RBP-Jκ conditional KO mice, constitutive Notch signaling in vivo and in vitro, IL-7 supplementation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genomic identification of novel promoter, genetic KO with specific phenotype, IL-7 functional rescue; single lab\",\n      \"pmids\": [\"25429074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IL-7Rα is expressed on fetal monocytes during differentiation into tissue-resident macrophages (trMacs). Blockade of IL-7R function during late gestation specifically impairs establishment of fetal-derived trMacs in vivo. Yolk sac erythromyeloid progenitors do not express IL-7R and yolk sac hematopoiesis is unperturbed in IL-7R-deficient mice, demonstrating a distinct fetal myeloid role for IL-7Rα.\",\n      \"method\": \"Il7r-Cre lineage tracing, IL-7R-deficient mice, IL-7R blockade during gestation, fetal monocyte in vitro differentiation, IL-7Rα surface expression tracking across fetal development\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple complementary approaches (lineage tracing, KO, antibody blockade, in vitro differentiation) converging on same mechanistic conclusion in one study\",\n      \"pmids\": [\"31332039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IL-7/IL-7Rα signaling withdrawal reduces POT1 protein synthesis, a component of the telomere-protective shelterin complex, leading to telomere erosion and activation of the p53 pathway. In IL-7Rα/p53 double-null mice, loss of apoptosis uncovers augmented thymic lymphomagenesis with chromosomal anomalies.\",\n      \"method\": \"IL-7Rα null/p53 null double KO mice, POT1 protein expression assays, telomere length analysis, chromosomal analysis of lymphomas\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic double KO with molecular mechanism (POT1 regulation), single lab\",\n      \"pmids\": [\"22281704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Ikaros directly binds the IL7R promoter and suppresses its expression; loss of Ikaros function in B-ALL is associated with high IL7R expression. Casein kinase inhibition (which increases Ikaros function) suppresses IL7R expression in an Ikaros-dependent manner.\",\n      \"method\": \"Ikaros ChIP at the IL7R promoter, casein kinase inhibitor treatment, Ikaros knockdown/overexpression with IL7R expression readout\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for direct binding plus pharmacological and genetic perturbation, single lab\",\n      \"pmids\": [\"27322554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IL-7 signaling through CD127 (IL-7Rα) in monocytes engages STAT5-coordinated transcriptional programs that restrain inflammatory gene expression. CD127-positive monocytes display hypoinflammatory phenotypes within highly inflammatory environments (COVID-19 and rheumatoid arthritis).\",\n      \"method\": \"Single-cell transcriptomics of human inflammatory monocytes, flow cytometry, functional IL-7 stimulation assays measuring inflammatory gene expression\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — single-cell transcriptomics plus functional IL-7 stimulation experiments, validated in two disease contexts\",\n      \"pmids\": [\"35015026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IL7Rα, but not Flk2, is intrinsically required for HSC reconstitution of tissue-resident lymphoid cells (B1a, marginal zone B cells, lung ILC2s, and Tregs). IL7Rα-deficient environments also impair TLC reconstitution upon transplantation, revealing a cell-extrinsic (niche) role for IL7Rα in TLC establishment.\",\n      \"method\": \"Flk2-Cre and Il7r-Cre lineage tracing, Flk2 and IL7Rα single and double KO mice, reciprocal bone marrow transplants\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO and reciprocal transplantation establishing both cell-intrinsic and cell-extrinsic roles, multiple TLC populations analyzed\",\n      \"pmids\": [\"35072209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Inducible deletion of IL-7Rα specifically on peripheral CD4+ T cells leads to gradual, substantial decrease in CD4+ T cell numbers and prevents EAE development. IL-7Rα-deficient CD4+ T cells show decreased numbers and reduced production of TNF, IFN-γ, IL-17A, GM-CSF, and reduced antigen-specific proliferation.\",\n      \"method\": \"Il7rafl/fl/CD4CreERT2 inducible conditional KO mice, EAE model, flow cytometry, cytokine production assays, MOG-specific T cell tracking\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible cell-type-specific KO with clear functional readouts, EAE pathogenesis linkage, antigen-specific T cell analysis\",\n      \"pmids\": [\"39380064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IL-7 stimulation promotes sCD127 mRNA expression and sCD127 (soluble IL-7Rα) release from CD8+ T cells via a PI3K-dependent pathway, and enhances CD8+ T cell cytotoxicity. PI3K inhibition dampens IL-7-induced elevation of CD8+ T cell cytotoxicity.\",\n      \"method\": \"IL-7 stimulation of primary human CD8+ T cells, PI3K pathway inhibitors, sCD127 ELISA, mRNA measurement, cytotoxicity co-culture assays\",\n      \"journal\": \"BMC immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological inhibitor used (not genetic), single lab, limited mechanistic depth\",\n      \"pmids\": [\"35850640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TSLP or IL-7 (both signaling via IL-7Rα) can provide the critical signal for human B-cell production. In vitro human B-cell production is almost completely blocked without IL-7Rα stimulation. In xenograft models, human pro-B cell production depends on IL-7 (neutralizable by anti-IL-7 antibody), and this loss can be restored by physiological levels of human TSLP.\",\n      \"method\": \"In vitro xenograft models of human B-cell development, IL-7 neutralizing antibody, TSLP supplementation, pro-B cell quantification\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional xenograft model with antibody neutralization and ligand rescue, single lab\",\n      \"pmids\": [\"27325567\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IL-7Rα (IL7R) is a transmembrane cytokine receptor subunit that, together with γc (IL-2Rγ), forms the functional IL-7 receptor; glycosylation of the IL-7Rα ectodomain dramatically enhances IL-7 binding affinity, and ligand binding triggers JAK1/JAK3-mediated JAK/STAT5, PI3K/Akt, and Notch signaling to drive T-cell (and, in mice, B-cell) development, homeostasis, Treg generation, and ILC development—with receptor internalization via clathrin-coated pits being required for efficient signaling, followed by JAK3-dependent lysosomal/proteasomal degradation; IL7R expression is dynamically regulated at the transcriptional level by DNA methylation, cytokine-induced GFI1-mediated repression, Ikaros, and Notch-RBP-Jκ signaling, and at the post-translational level by IL-7-driven endocytosis and IL-15-dependent downregulation; alternative splicing of exon 6 (regulated by CPSF1 and DDX39B) controls the ratio of membrane-bound to soluble IL-7Rα, with soluble IL-7Rα potentiating IL-7 bioavailability; IL-7Rα sequesters γc by direct extracellular association, limiting IL-2R signaling; gain-of-function mutations introducing unpaired cysteines in the juxtamembrane/transmembrane region drive IL-7Rα homodimerization and constitutive JAK1 signaling independently of ligand, causing T-ALL; and overexpression of wild-type IL-7Rα also promotes T-cell leukemogenesis via PI3K/Akt, JAK/STAT, and Bcl-2 pathways.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"IL7R encodes IL-7Rα, the ligand-specific subunit of the IL-7 receptor that, paired with the common γc chain, transduces signals required for lymphoid development and homeostasis; in humans, loss-of-function mutations cause T(-)B(+)NK(+) severe combined immunodeficiency, establishing a non-redundant requirement for IL-7Rα in T-cell but not NK-cell development [#0]. Glycosylation of the IL-7Rα ectodomain accelerates the on-rate for IL-7 and raises binding affinity ~300-fold, and SCID mutations map outside the ligand interface, implicating folding defects rather than disrupted contact [#2]. Engaged receptor signals through a Tyr449 SH2-binding motif to STAT5, driving Mcl-1 expression and supporting B-lineage survival and immunoglobulin rearrangement [#14], and the same receptor controls regulatory T-cell development, where either IL-7 or TSLP can supply the required IL-7Rα signal [#7]. Beyond canonical lymphopoiesis, IL-7Rα directs ILC3 differentiation via polyglutamylation-coupled STAT5/Sall3 signaling [#15], supports establishment of fetal-derived tissue-resident macrophages [#24] and tissue-resident lymphoid cells [#28], and restrains inflammatory gene expression in monocytes [#27]. Receptor abundance is tightly governed: IL-7 triggers clathrin-mediated endocytosis and JAK3-dependent lysosomal/proteasomal degradation that is itself required for efficient signaling [#3], cytokines repress IL7R transcription via GFI1 [#1], and DNA methylation [#9], Ikaros [#26], and Notch–RBP-Jκ [#23] further tune expression. Competing splicing/polyadenylation controlled by CPSF1 [#11] and the helicase DDX39B [#12] sets the ratio of membrane-bound to soluble IL-7Rα, the latter potentiating IL-7 bioavailability and modulating autoimmunity [#8]. IL-7Rα also sequesters γc to limit IL-2R signaling, explaining why its downregulation maximizes Treg IL-2 responsiveness [#16]. In disease, somatic gain-of-function mutations introducing unpaired cysteines drive ligand-independent IL-7Rα homodimerization and constitutive JAK1 signaling in T-ALL [#4] or assemble with CRLF2 to signal in B-ALL [#5], while overexpression of wild-type IL-7Rα alone is sufficient to promote T-cell leukemogenesis through PI3K/Akt, JAK/STAT, Notch, and Bcl-2 [#17], and IL-7Rα is required for leukemia-initiating cell activity [#19].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established that IL-7Rα signaling is non-redundantly required for human T-cell development, distinguishing its role from γc and JAK3.\",\n      \"evidence\": \"Genetic analysis of SCID patients with defective IL7R, compared with XSCID and JAK3-SCID phenotypes\",\n      \"pmids\": [\"9843216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which downstream effectors are essential\", \"B-cell and NK lineage requirements left to ortholog studies\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined IL-7Rα as one of two parallel survival inputs for lymphoid progenitors, acting separately from the E2A/caspase-3 pathway.\",\n      \"evidence\": \"IL-7Rα/E47 double-knockout mice with caspase-3 assays and Bcl-2 rescue\",\n      \"pmids\": [\"11782430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of the IL-7Rα survival effector not pinpointed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Revealed a homeostatic feedback whereby prosurvival cytokines repress IL7R transcription to share limiting IL-7, identifying GFI1 in CD8 T cells.\",\n      \"evidence\": \"Transcriptional reporter assays and GFI1 functional analysis in primary T cells\",\n      \"pmids\": [\"15308108\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CD4 repressor remained unidentified\", \"Did not map GFI1 binding directly on the locus\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Explained how IL-7Rα achieves high-affinity ligand binding and reframed SCID mutations as folding rather than interface defects.\",\n      \"evidence\": \"Crystal structure of glycosylated and unglycosylated IL-7/IL-7Rα complex with biophysical binding measurements\",\n      \"pmids\": [\"19141282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of the ternary IL-7/IL-7Rα/γc signaling complex\", \"Glycan-specific contributions to signaling not measured\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed receptor internalization is not merely downregulation but a required step for efficient signaling, coupling endocytosis to JAK3-dependent degradation.\",\n      \"evidence\": \"Live-cell imaging, clathrin and JAK inhibitors, pulse-chase degradation in T cells\",\n      \"pmids\": [\"20190194\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Adaptor proteins linking IL-7Rα to clathrin not identified\", \"How endocytosis enhances signaling mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified oncogenic gain-of-function mutations that drive ligand-independent IL-7Rα homodimerization and constitutive JAK1 activation in T-ALL, and γc-independent assembly with CRLF2 in B-ALL.\",\n      \"evidence\": \"Disulfide bond biochemistry, cytokine-independent growth, cysteine mutagenesis, in vivo tumor formation\",\n      \"pmids\": [\"21892159\", \"21536738\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define why JAK1 rather than JAK3 is engaged\", \"Therapeutic vulnerability not yet mapped in this study\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated that Vps34/class III PI3K routes internalized IL-7Rα through retromer recycling, linking endosomal trafficking to surface receptor levels and T-cell survival.\",\n      \"evidence\": \"Conditional Vps34 knockout mice, subcellular fractionation, endosomal marker localization, flow cytometry\",\n      \"pmids\": [\"22021616\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct interaction of retromer with IL-7Rα not shown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established competing splicing/polyadenylation, mediated by CPSF1, as a mechanism setting the soluble-to-membrane IL-7Rα ratio.\",\n      \"evidence\": \"RNA affinity chromatography/MS, CPSF1 knockdown, polyadenylation-signal mutagenesis, splicing assays\",\n      \"pmids\": [\"23151878\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological triggers altering CPSF1 activity unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Dissected IL-7-driven CD127 downregulation into a rapid JAK-independent protein loss and a delayed STAT5-dependent transcriptional suppression.\",\n      \"evidence\": \"Human CD8 T cell stimulation with JAK inhibitor, protein/mRNA kinetics, dose-response\",\n      \"pmids\": [\"23207282\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism of the early JAK-independent loss not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified IL-15, not IL-7 or Foxo1, as the organ-specific driver of CD127 downregulation on bone marrow memory CD8 T cells.\",\n      \"evidence\": \"Multiple cytokine and receptor KO mouse comparisons with mRNA quantification\",\n      \"pmids\": [\"22539288\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Downstream transcriptional mediator not identified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linked IL-7Rα signaling withdrawal to telomere protection via POT1 and p53, uncovering a tumor-suppressive axis whose loss enables thymic lymphomagenesis.\",\n      \"evidence\": \"IL-7Rα/p53 double-null mice, POT1 expression, telomere and chromosomal analysis\",\n      \"pmids\": [\"22281704\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism of POT1 translational control not detailed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined soluble IL-7Rα as a functional modulator that potentiates IL-7 bioactivity and exacerbates autoimmunity by limiting cytokine consumption.\",\n      \"evidence\": \"Binding affinity measurements plus in vitro signaling and in vivo homeostatic expansion and EAE models\",\n      \"pmids\": [\"23610432\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo source and concentration thresholds of sIL-7Rα not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapped the IL-7Rα Tyr449 STAT5-recruiting motif as essential for B-lineage survival via Mcl-1 and for immunoglobulin rearrangement, distinct from Bcl-2 rescue.\",\n      \"evidence\": \"Tyr449Phe knock-in mice, STAT5 phosphorylation, Bcl-2 transgene rescue, B-cell staging\",\n      \"pmids\": [\"25143441\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other cytoplasmic tyrosines' contributions not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed that polyglutamylation/deglutamylation of IL-7Rα tunes STAT5-driven Sall3 induction to control ILC3 development, a non-canonical post-translational regulatory layer.\",\n      \"evidence\": \"CCP2, TTLL4/TTLL13 KO and IL-7Rα E446A knock-in mice with STAT5 and Sall3 readouts\",\n      \"pmids\": [\"28794449\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether glutamylation regulates other IL-7Rα-dependent lineages unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established DDX39B as an activator of IL7R exon 6 inclusion whose translation-reducing variant raises soluble IL-7Rα, with genetic epistasis to IL7R in MS risk.\",\n      \"evidence\": \"Genetic epistasis, splicing reporters, DDX39B over/knockdown, translation reporters\",\n      \"pmids\": [\"28340352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How DDX39B mechanistically promotes exon inclusion not fully resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed IL-7Rα is required for leukemia-initiating cell activity in Notch1-driven T-ALL and for xenograft engraftment across leukemia types.\",\n      \"evidence\": \"Il7r-deficient Notch1 leukemia transplantation and patient-derived xenografts\",\n      \"pmids\": [\"31530562\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Effector pathway sustaining LIC self-renewal not isolated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified a physical IL-7R/CXCR4 platform recruiting BCR-ABL1 and JAKs in Ph+ ALL and a kinase-inhibitor-induced IL7R upregulation enabling survival escape.\",\n      \"evidence\": \"Co-IP of IL7R with CXCR4, patient-derived xenotransplantation, anti-IL7R antibody treatment\",\n      \"pmids\": [\"32581241\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Stoichiometry and directness of the multi-protein platform not fully defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended IL-7Rα function beyond lymphocytes by showing it is required to establish fetal-derived tissue-resident macrophages.\",\n      \"evidence\": \"Il7r-Cre lineage tracing, IL-7R-deficient mice, gestational blockade, in vitro differentiation\",\n      \"pmids\": [\"31332039\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling output in myeloid context not mechanistically dissected\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated that IL-7Rα abundance limits IL-2R signaling by sequestering γc through extracellular pre-association, rationalizing IL-7Rα downregulation in Tregs.\",\n      \"evidence\": \"IL-7Rα overexpression including tailless mutant, STAT5 readouts, γc Co-IP\",\n      \"pmids\": [\"32791329\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Endogenous physiological relevance beyond overexpression not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed wild-type IL-7Rα overexpression alone is sufficient to drive T-cell leukemogenesis via PI3K/Akt, Notch, JAK/STAT and Bcl-2, with pharmacological vulnerabilities.\",\n      \"evidence\": \"Inducible transgenic and Rosa26 knock-in mice, immunophenotyping, pathway inhibitors\",\n      \"pmids\": [\"33970999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which established tumors become IL-7Rα-level-independent unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined an anti-inflammatory IL-7/CD127/STAT5 program in human monocytes, expanding IL-7Rα biology into innate inflammation control.\",\n      \"evidence\": \"Single-cell transcriptomics and IL-7 stimulation in COVID-19 and rheumatoid arthritis monocytes\",\n      \"pmids\": [\"35015026\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single study\", \"STAT5 target genes restraining inflammation not enumerated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Distinguished cell-intrinsic and niche (extrinsic) roles of IL-7Rα in establishing tissue-resident lymphoid cells beyond conventional lymphopoiesis.\",\n      \"evidence\": \"Flk2- and Il7r-Cre lineage tracing, single/double KO mice, reciprocal transplants\",\n      \"pmids\": [\"35072209\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the IL-7Rα-dependent niche signal not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established a continuous peripheral requirement for IL-7Rα on mature CD4 T cells to sustain numbers, effector cytokine output, and autoimmune (EAE) pathogenesis.\",\n      \"evidence\": \"Inducible CD4-specific IL-7Rα KO mice, EAE model, cytokine and antigen-specific proliferation assays\",\n      \"pmids\": [\"39380064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether effect reflects survival versus functional reprogramming not fully separated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple post-translational regulatory layers (endocytosis, polyglutamylation, γc sequestration) are integrated with transcriptional and splicing control to set context-specific IL-7Rα output remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking trafficking, modification, and isoform balance\", \"Structure of the active signaling complex on the cell surface lacking\", \"Effectors driving non-lymphoid (myeloid, niche) IL-7Rα functions undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 4, 14]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [2, 8]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [16, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 16, 2]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [8, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 4, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 7, 29]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [14, 15, 24, 28]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 5, 17, 19]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [11, 12]}\n    ],\n    \"complexes\": [\n      \"IL-7 receptor (IL-7Rα/γc)\",\n      \"IL-7Rα/CRLF2 (TSLP receptor)\"\n    ],\n    \"partners\": [\n      \"IL2RG\",\n      \"JAK1\",\n      \"JAK3\",\n      \"CRLF2\",\n      \"CXCR4\",\n      \"STAT5\",\n      \"TTLL4\",\n      \"CCP2\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}